Skip to main content
Biology LibreTexts

Drug Development

The difficulty lies, not in the new ideas, but in escaping the old ones, which ramify, for those brought up as most of us have been, into every corner of our minds. - John Maynard Keynes

Typically, drugs have been found by an almost serendipitous process. Active molecules are usually derived from biological sources such as bacteria, fungi, plants, etc. Different molecular species are extracted which, in bioassays, seem to inhibit a target biological function or specific enzyme. The structure is then solved, and medicinal chemists "decorate" the molecule by covalently modifying the initial structure in ways which will improve its medicinal value (decreased Kd, increased solubility, longer half-life, fewer side effects, etc.) Bioactive structures are often found to be peptides or modified peptides. One main job of a medicinal chemists is to synthesize a peptidomimetic with different functional groups than are found in peptides, making the structure more stable to endogenous proteases. Newer methods involve molecular modeling and rational drug design. Computers can be used to analyze the structure and activity of a large number of different molecules which inhibit the target enzyme. By doing Quantitative Structure Activity Result studies (QSAR), the computer can be used to hypothesize the structure of the "perfect" inhibitor, which can then be synthesized. In an analogous fashion, the active site of the target enzyme can be constructed from this data, without the benefit of having a crystal and NMR structure.  

Drugs can be designed to inhibit enzymes or to bind to sites on receptors (either in the membrane or the cytoplasm). When bound to a receptor, the drug ligand may mimic the natural ligand and lead to expression of the biological activity of the receptor. In this case, the drug is an called an agonist of the normal ligand. In general, if the drug inhibits the activity of the bound receptor, the drug is called an antagonist. Examples are show below. Notice the similarity and differences in structures between the normal ligand and the drug. A more detailed description of agonist and antagonist will be present later in the discussion of enzyme inhibitors.

Figure: Receptor agonists/antagonist I


01 recagonantagi.gif

Figure: Receptor agonists/antagonist II

02 recagonantagii.gif


Combinatorial Drug Development

Instead of searching various organisms to find a possible drug from all the extractable molecules of the organism, people are now synthesizing an enormous number of randomly constructed molecules, and then selecting active molecules from this random pool by binding or other bioassays. Solid phase synthesis of random peptides or nucleic acids can be used to generate thousands of possible test inhibitors. Those peptides or oligonucleotides that bind flurorescent-labeled protein can be determined, as shown below.

 Figure: Combinatorial Drug Development.

03.0 comblibr.JPEG

These structures can then be decorated or used to design peptide or oligonucleotide mimetics, which would be more resistant to enzymatic degradation. Another way to make a large library of peptide inhibitors is to make them using genetic engineering.

Recently, peptides made of D-amino acids have been synthesized. These are much more resistant to proteases than normal L-amino acid peptides. D amino acid peptides can only be made in the lab, and not through genetic engineering. An intriguing variation of this technique has recently been developed. Investigators have synthesized entire proteins in the lab using D-amino acids. Combinatorial L-peptide libraries were made using genetic engineering in bacteria. L-peptides were selected that bound with high affinity to the D-protein. The corresponding D-peptides were made in the lab, which then were found to bind to the normal L-protein.

In another combinatorial technique, single stranded RNA molecules called aptamers can be synthesized and tested for the binding/inhibitory activity for a enzyme. RNA molecules, which can form complex secondary and tertiary structure, can also present, given the appropriate sequence, a complementary binding surface to sites on proteins. Aptamers with high affinity are sequenced. Bases that appear to be necessary for high affinity binding are identified by comparing the sequence of different aptamers. This knowledge is then used to synthesize even tighter binding aptamers, in an process that mimics evolutionary selection for high affinity binding. Such a high affinity aptamer was recently made to bind to and inhibit Factor IXa, an active enzyme required for initiation and propagation of blood clotting. Traditional anticoagulant drugs are extremely valuable in treating and preventing inappropriate clot formation, which can lead to strokes (brain attacks) and heart attacks.The problem with these drugs is that they must not tip the clotting/anticlotting balance to far in the direction of clot prevention, since there are many times when clot formation is the appropriate biological response (such as in the prevention of hemorrhagic stoke). Rusconi et al. realized that once they had developed the high affinity aptamer for factor IXa binding, they immediately could synthesize an anedote for the aptamer. It would have a complementary sequence to the Factor IXa binding bases of the drug aptamer, that would allow it to bind to the original apatmer and form a double-stranded RNA sequence. The crystal structure of the homodimer transcription factor, NF-kB (p50)2 bound to an RNA aptamer has been determined. The RNA sequence is dissimilar to the DNA sequence which binds the transcription factor, even though both have similar dissociation constants. 

Computer Design of Drugs

Given a 3D structure of a protein, a clever synthetic chemist should be able to design a drug to fit into any "pit or canyon" that serves as a binding site for a biological ligand.Virtual reality simulations showing the protein target and drug with feedback on binding interactions provided to hand inputs using a haptic device are being used in drug design.

Many computer programs exists as well that will "dock" small ligand to active sites on large biological molecules.  

Drugs are intended to be target-specific; however, many drugs interact with other physiological targets which may result in side effects. In order to understand drug-target associations and predict new targets for established drugs, Keiser M. et. all used a similarity ensemble approach (SEA) to compare 3,665 FDA approved drugs to hundreds of different ligands. In this approach, they compared targets based on the similarity of ligands that bind to the different targets. This comparison predicted 257 drug-target associations that were not noted in either the MDL Drug Data Report or the World of Molecular Bioactivity database. Of these, they then tested 30 of the predictions. 14 of the 30 were found to have 23 previously unknown targets.

Keiser, then went on to analyze if these new targets were biologically relevant. To do so, they used the following criteria:

  • Did the new targets contribute to the primary activity of the drug,
  • Did  they cause side effects, or
  • Were  the new targets unrelated by sequence, structure, and function to the typical target.

When testing whether some of the new targets were primary sites of action, they noted that for some of the different drugs, the binding affinity was higher for the new target than it was for the intended target. For example, Keiser et. all used SEA to compile different ligands for dimethyltryptamine (DMT). Based on this, and DMT’s side effects, they tested the binding affinity of DMT to different receptors and found that DMT would bind five of these. All of these receptors had substantially greater affinities for DMT than the intended target. Some of the new off-targets also gave insight into several drugs’ side effects. Finally, there were four drugs that did not bind to targets that were related by sequence or structure to their intended targets. However, these new targets were related to the intended targets in that they had similar ligands regulating their activities. Overall, Keiser et. all were able to use the similarity ensemble approach based on ligand similarities to map new off-target associations for drugs. This approach can be used to gain better understanding of drug associations and to predict new molecular targets

In Situ Click Chemistry: Using Enzymes as Synthetic Templates for Drug Synthesis

Drugs that inhibit enzymes typically bind to the active site of the enzyme where catalysis occurs. Binding of an inhibitor precludes binding of the normal reactants (substrates) for the enzyme, inhibiting its activity. In a new strategy, two small reactive molecules selected to bind independently in the active site can covalently react with each other to form a new drug with very high specificity and very high binding affinity (low Kd). Recently this has been used to synthesize noncovalent inhibitors of the enzyme acetylcholinesterase (Barry Sharpless Lab, Scripps Lab). The reactive groups chosen in the example below are azide and acetylene derivatives, which when held in close approximation in the binding site of the enzyme undergo a cycloaddition reaction to form a triazole.

The actual mechanism (not the simplified version show below) requires catalysis by cupper ions which forms a complex with the acteylide (deprotonated acetylene) effectively decreasing the pKa of the acetylene functional group, making it a better nucleophile.A dicopper intermediate is suggested in which the azide interacts with the second copper. Subsequen rearrangment lead to the triazole products.

Figure: Test tube and in situ synthesis of triazole inhibitors.

04 azideacetylenetempl.gif


Multivalency and Binding: Design of Inhibitors

In the previous study guide on binding and transcription, we discussed how a protein might bind DNA cooperatively if it interacts with a pre-bound protein adjacent to its normal binding site as well as its own binding site. The protein-protein interaction effectively reduces the apparent koff of the protein for its DNA binding site, which decreases the apparent Kd. Imagine a variation on this. Consider what might happen if a ligand for a macromolecule receptor found on the cell membrane was present in multiple copies. That is, what if the ligand was multivalent?What if the receptor was also multivalent? Both these cases are often found when complex ligands (bearing complex carbohydrates, for example) are present on the presenting ligand (a virus or bacteria, for example) and the macromolecule receptor is a cell surface protein. An interaction between the multivalent ligand and the receptor is necessary for the initial biological interaction between them.  

By decreasing the apparent koff as described above, multiple weak binding interactions can be effectively turned into strong interactions. Creating multivalent drug inhibitors of viral or bacterial interactions with cell membrane receptors would increase their efficacy. For example, consider the binding of the influenza virus to its receptor on a cell. Two viral proteins, hemagglutinin, as well as neuraminidase, binds to sialic acid residues on the glycoproteins receptors of the cells. A single, monovalent sialic acid derivative (acting as a drug) would be a low affinity inhibitor of the viral-cell interaction. A multivalent inhibitor, in which multiple sialic acid derivatives were covalently attached to a liposome proved to be a much more effective inhibitor since it could bind to multiple hemagglutinin and neuramindase molecules on the viral surface with an apparent lower Kd. This inhibitor is 1000X as potent as the monovalent inhibitor. This technique can be used not only to inhibit, but also activate biological reactions.

Figure: Multivalent inhibitor of flu virus

09 multivalentfluinhib.gif

Other mechanism can also account for the amplified effects of multivalent ligands in addition to the effects on koff (which is related to the effective local concentration of the ligand at the receptor site - an effect also called the chelate effect). These include ligand-induced clustering of receptors on the cell surface and binding of multivalent ligands to more than one site or subsite on the receptor. These are illustrated below.

Figure: Multivalent Ligand Binding Models

10.0 multivalenceybertozzi.JPEG

Targeted Delivery of Drugs to Tumor Cells

The toxic effects of chemotherapeutic drugs might be eliminated if the drugs could be targeted to tumor cells and not to normal cells. Tumor cells presumably display unique protein molecules (tumor antigens) on their cell surface membranes that are not found on normal cell membranes. Drugs must enter the circulatory system of the specific targeted organ before they can be taken up by that organ. The endothelial cells that line the inner surface of blood vessels must display different proteins depending on the organ they are in, since circulating cells that interact with blood vessels in a specific organ appear to bind only to the endothelial cells in the specific organ. These cell and tissue-specific endothelial cell surface receptors impart specificity in binding.A recent study by Oh et al. demonstrated the presence of different proteins on endothelial cells found in blood vessels of normal mouse lungs and lung tumors. They injected silica particles into the blood. The particles bound to endothelial cells membranes. They homogenized, centrifuged and purified membrane-fractions bound to the silicon particles. The membranes were highly enriched in endothelial cells and caveolae, which are small indentations into the membrane and represent sites for the uptake of molecules, viruses, etc. into the cell. Molecular targets (such as viruses) could bind to receptors in the caveolae, and then through a process of invagination be taken up into the cell. The inner leaflet of the caveolae is lined with a protein called caveolin. Two endothelial cell transmembrane proteins, aminopeptidase P and annexin A1 were found specifically in normal and tumor lung endothelial cells, respectively. When given to rats with lung tumors, radioactive-labeled antibodies to annexin A1prolonged the life span of the rats.


  1. Moellering, R. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 171 and 182 (2009)
  2. Keiser, M. et al. Predicting new molecular targets for known drugs. Nature 462, 167 and 175 (2009)
  3. Oh, P. et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature. 429, pg 629 (2004)
  4. Dumoulin, M. et al. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature, 424, pg 783 (2003).
  5. Huang, D. et al. Crystal structure of NF-kB (p50)2 complexed to a high affinity RNA aptamer. Proc. Natl. Acad. Sci. USA. 100, pg 9268 (2003)
  6. Sanchez, I. et al. Pivotal Role of oligomerization in expanced polyglutamine neurodegenerative disorders. Nature. 421, pg 373, (2003)
  7. Hammarstrom, P. et al. Prevention of Transthyretin Amyloid Disease by changing protein misfolding energetics. Science. 299, pg 713 (2003)
  8. Rusconi, C. et al. RNA apatmaers as reversible antagonists of coagulation factor IXA. Nature. 419, pg 90, 23 (2002)
  9. Zasloff. Antimicorbial peptides of multicellular organisms. Nature. 415, pg 389 (2002)
  10. RNA Interference: The Short Answer (blocking mRNA). Nature. 411 pg 428 (2001)
  11. Fernandez-Lopez et al. Rings of Destruction. (Cyclic peptides as drugs). Natuare. 412 pg 392, 452 (2001)
  12. Small but mighty timekeepers. (small RNA inhibition of translation) Nautre. 408, pg 37 (2000)
  13. Shokat et al. A Chemistry Set for Life. (Chemical genetics: inhibitors designed for specific gene products)*** Nature 407, pg 282, 395 (2000)
  14. Clark et al. Molecular Switches in Metastasis. Nature. 406. pg 466, 532 (2000)
  15. Root et al. Protein Design of an HIV-1 Entry Inhibitor. Science. 291, pg 884 (2001)
  16. Tyler et al. Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. PNAS, Vol. 96, Issue 12, 7053-7058, June 8, 1999.  
  17. Interfering with Gene Expression (silencing at the mRNA level). Science. 288, pg 1370 (2000)
  18. Gellman et al. Slaying Bacteria with b-peptides. Nature. 404, pg 565 (2000)
  19. RNA interference (RNAi by short RNAs that demonstrate transcriptional silencing). Science. 287, pg 2431, 2494 (2000)
  20. Evans and Relling. Pharmocogenomics: Translating function genomics into rational therapeutics. Science. 286, pg 487 (1999)
  21. Kiessling, L et al. Synthetic multivalent ligands in the exploration of cell-surfaceCurrent Opinion in Chemical Biology, 4, pg696 (2000)